keyword
https://read.qxmd.com/read/34587188/interferon-beta-for-the-treatment-of-multiple-sclerosis-in-the-campania-region-of-italy-merging-the-real-life-to-routinely-collected-healthcare-data
#1
JOURNAL ARTICLE
Marcello Moccia, Giuseppina Affinito, Antonio Capacchione, Roberta Lanzillo, Antonio Carotenuto, Emma Montella, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino
BACKGROUND: We aim to overcome limitations of previous clinical and population-based studies by merging a clinical registry to routinely-collected healthcare data, and to specifically describe differences in clinical outcomes, healthcare resource utilization and costs between interferon beta formulations for multiple sclerosis (MS). METHODS: We included 850 patients with MS treated with interferon beta formulations, from 2015 to 2019, seen at the MS Clinical Care and Research Centre (Federico II University of Naples, Italy) and with linkage to routinely-collected healthcare data (prescription data, hospital admissions, outpatient services)...
2021: PloS One
https://read.qxmd.com/read/34425763/clinical-characteristics-of-middle-aged-and-older-patients-with-ms-treated-with-interferon-beta-1b-post-hoc-analysis-of-a-2-year-prospective-international-observational-study
#2
JOURNAL ARTICLE
Francesco Patti, Javier Nicolas Penaherrera, Lorissa Zieger, Eva-Maria Wicklein
BACKGROUND: Despite trends towards the increased age of patients living with multiple sclerosis (MS), little is known about the response of older adults with MS to disease-modifying therapies (DMTs). Thus, a post-hoc analysis was undertaken using data from a 2-year, international, non-interventional, prospective cohort study (NCT00787657; BEACON: BEtaferon prospective study on Adherence, COping and Nurse support) of patients above the age of 40 years with MS and starting interferon beta-1b (IFNB-1b) treatment within 6 months before study entry...
August 23, 2021: BMC Neurology
https://read.qxmd.com/read/32847587/persistence-adherence-healthcare-resource-utilisation-and-costs-for-interferon-beta-in-multiple-sclerosis-a-population-based-study-in-the-campania-region-southern-italy
#3
JOURNAL ARTICLE
Marcello Moccia, Ilaria Loperto, Roberta Lanzillo, Antonio Capacchione, Antonio Carotenuto, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino
BACKGROUND: To differentiate five formulations of Interferon Beta for the treatment of multiple sclerosis (MS) in clinical practice, by analysing persistence, adherence, healthcare resource utilisation and costs at population level. METHODS: In this population-based study, we included individuals with MS living in the Campania Region of Italy from 2015 to 2017, on treatment with intramuscular Interferon Beta-1a (Avonex® = 618), subcutaneous pegylated Interferon Beta-1a (Plegridy® = 259), subcutaneous Interferon Beta-1a (Rebif® = 1220), and subcutaneous Interferon Beta-1b (Betaferon® = 348; and Extavia® = 69)...
August 26, 2020: BMC Health Services Research
https://read.qxmd.com/read/32532085/broad-spectrum-host-based-antivirals-targeting-the-interferon-and-lipogenesis-pathways-as-potential-treatment-options-for-the-pandemic-coronavirus-disease-2019-covid-19
#4
JOURNAL ARTICLE
Shuofeng Yuan, Chris Chun-Yiu Chan, Kenn Ka-Heng Chik, Jessica Oi-Ling Tsang, Ronghui Liang, Jianli Cao, Kaiming Tang, Jian-Piao Cai, Zi-Wei Ye, Feifei Yin, Kelvin Kai-Wang To, Hin Chu, Dong-Yan Jin, Ivan Fan-Ngai Hung, Kwok-Yung Yuen, Jasper Fuk-Woo Chan
The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) signals an urgent need for an expansion in treatment options. In this study, we investigated the anti-SARS-CoV-2 activities of 22 antiviral agents with known broad-spectrum antiviral activities against coronaviruses and/or other viruses. They were first evaluated in our primary screening in VeroE6 cells and then the most potent anti-SARS-CoV-2 antiviral agents were further evaluated using viral antigen expression, viral load reduction, and plaque reduction assays...
June 10, 2020: Viruses
https://read.qxmd.com/read/32300060/vitamin-d-smoking-ebv-and-long-term-cognitive-performance-in-ms-11-year-follow-up-of-benefit
#5
MULTICENTER STUDY
Marianna Cortese, Kassandra L Munger, Elena H Martínez-Lapiscina, Christian Barro, Gilles Edan, Mark S Freedman, Hans-Peter Hartung, Xavier Montalbán, Frederick W Foley, Iris Katharina Penner, Bernhard Hemmer, Edward J Fox, Sven Schippling, Eva-Maria Wicklein, Ludwig Kappos, Jens Kuhle, Alberto Ascherio
OBJECTIVE: To investigate whether vitamin D, smoking, and anti-Epstein-Barr virus (EBV) antibody concentrations predict long-term cognitive status and neuroaxonal injury in multiple sclerosis (MS). METHODS: This study was conducted among 278 patients with clinically isolated syndrome who participated in the clinical trial BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and completed the 11-year assessment (BENEFIT-11). We measured serum 25-hydroxyvitamin-D (25(OH)D), cotinine (smoking biomarker), and anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) immunoglobulin G (IgG) at baseline and at months 6, 12, and 24 and examined whether these biomarkers contributed to predict Paced Auditory Serial Addition Test (PASAT)-3 scores and serum neurofilament light chain (NfL) concentrations at 11 years...
May 5, 2020: Neurology
https://read.qxmd.com/read/31359863/assessment-of-medication-adherence-using-a-medical-app-among-patients-with-multiple-sclerosis-treated-with-interferon-beta-1b-pilot-digital-observational-study-promybetaapp
#6
JOURNAL ARTICLE
Volker Limmroth, Klaus Hechenbichler, Christian Müller, Markus Schürks
BACKGROUND: Accurate measurement of medication adherence using classical observational studies typically depends on patient self-reporting and is often costly and slow. In contrast, digital observational studies that collect data directly from the patient may pose minimal burden to patients while facilitating accurate, timely, and cost-efficient collection of real-world data. In Germany, ~80% of patients with multiple sclerosis (MS) treated with interferon beta 1b (Betaferon) use an electronic autoinjector (BETACONNECT), which automatically records every injection...
July 29, 2019: Journal of Medical Internet Research
https://read.qxmd.com/read/30537798/characterization-of-cd4-and-cd8-t-cell-subsets-and-interferon-regulatory-factor-4-irf4-in-ms-patients-treated-with-fingolimod-fty-720-a-follow-up-study
#7
JOURNAL ARTICLE
Bahare Laribi, Mohammad Ali Sahraian, Mehdi Shekarabi, Rahimeh Emamnejad, Mohsen Marzban, Shokufeh Sadaghiani, Maryam Izad
Fingolimod is a novel immunomodulatory drug used in patients with relapsing multiple sclerosis (MS) which reversibly inhibits egress of lymphocytes from lymph nodes. In this longitudinal study, the frequency of Interferon- gamma (IFN-γ)+, IL4+, IL17+ and IL10+ CD4+ and CD8+ T cell subsets were measured in Fingolimod treated patients before and after 12 months'(12M) therapy using flow cytometry and compared to those of naive, Betaferon treated MS patients and healthy individuals. Additionally, the level of transcription factor IRF4 and IL-6, IL-23, TGF-β1 cytokines, required for differentiation of IL-17+ T cells, were assessed by RT-PCR and ELISA, respectively...
August 12, 2018: Iranian Journal of Allergy, Asthma, and Immunology
https://read.qxmd.com/read/30178232/immunoregulatory-effects-of-silymarin-on-proliferation-and-activation-of-th1-cells-isolated-from-newly-diagnosed-and-ifn-%C3%A3-1b-treated-ms-patients
#8
JOURNAL ARTICLE
Fereshteh Navabi, Vahid Shaygannejad, Faezeh Abbasirad, Elaheh Vaez, Fahimeh Hosseininasab, Mohammad Kazemi, Omid Mirmosayyeb, Fereshteh Alsahebfosoul, Nafiseh Esmaeil
Multiple sclerosis (MS) is a central nervous system autoimmune disease characterized by demyelination. Autoreactive T cells mainly interferon gamma (IFN-γ) producing T helper cells (Th1) have an important role in MS pathogenesis. Silymarin is a unique blend produced from milk thistle (Silybum marianum) plant which its imunomodulatory role has been indicated in studies. In the present study, the effects of silymarin on isolated Th1 cells were investigated in newly diagnosed MS patients and those who received betaferon...
February 2019: Inflammation
https://read.qxmd.com/read/29796438/multiple-sclerosis-with-ophthalmologic-onset-case-report
#9
JOURNAL ARTICLE
Dănuţ Costin, Gabriela Mirela Pînzaru, Andra Mădălina Pătraşcu, Anca Moţoc, Andreea Dana Moraru
Ophthalmological and neurological signs and symptoms were assessed in a patient diagnosed with retrobulbar optic neuritis associated with multiple sclerosis (MS). The patient presented with progressive decrease of visual acuity, intermittent diplopia, paresthesia of the left arm and equilibrium disturbances. The complete ophthalmologic examination (clinical examination, visual field, optical coherence tomography) along with an MRI exam supported the diagnosis of MS with active lesions associated with retrobulbar optic neuritis...
January 2018: Romanian Journal of Ophthalmology
https://read.qxmd.com/read/29521573/effect-of-hla-drb1-alleles-and-genetic-variants-on-the-development-of-neutralizing-antibodies-to-interferon-beta-in-the-beyond-and-benefit-trials
#10
JOURNAL ARTICLE
Dorothea Buck, Till Fm Andlauer, Wilmar Igl, Eva-Maria Wicklein, Mark Mühlau, Frank Weber, Karl Köchert, Christoph Pohl, Barry Arnason, Giancarlo Comi, Stuart Cook, Massimo Filippi, Hans-Peter Hartung, Douglas Jeffery, Ludwig Kappos, Frederik Barkhof, Gilles Edan, Mark S Freedman, Xavier Montalbán, Bertram Müller-Myhsok, Bernhard Hemmer
BACKGROUND: Treatment of multiple sclerosis (MS) with interferon β can lead to the development of antibodies directed against interferon β that interfere with treatment efficacy. Several observational studies have proposed different HLA alleles and genetic variants associated with the development of antibodies against interferon β. OBJECTIVE: To validate the proposed genetic markers and to identify new markers. METHODS: Associations of genetic candidate markers with antibody presence and development were examined in a post hoc analysis in 941 patients treated with interferon β-1b in the Betaferon® Efficacy Yielding Outcomes of a New Dose (BEYOND) and BEtaseron® /BEtaferon® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) prospective phase III trials...
March 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/29318028/interferon-beta-1b-in-treatment-na%C3%A3-ve-paediatric-patients-with-relapsing-remitting-multiple-sclerosis-two-year-results-from-the-betapaedic-study
#11
JOURNAL ARTICLE
Jutta Gärtner, Wolfgang Brück, Almuth Weddige, Hannah Hummel, Christiane Norenberg, Jörg-Peter Bugge
Background and objective: Study evaluating Betaferon(R)'s safety and tolerability in paediatric patients with multiple sclerosis (BETAPAEDIC) is a prospective, open-label observational multicentre study to assess the safety and effectiveness of interferon beta-1b in paediatric patients with relapsing-remitting multiple sclerosis. Methods: Treatment-naïve patients (12-16 years) scheduled to start interferon beta-1b were enrolled with follow-up visits every six months for two years...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://read.qxmd.com/read/29049356/treatment-satisfaction-with-injectable-disease-modifying-therapies-in-patients-with-relapsing-remitting-multiple-sclerosis-the-stick-study
#12
JOURNAL ARTICLE
Oscar Fernández, Eduardo Duran, Teresa Ayuso, Luis Hernández, Inmaculada Bonaventura, Mireia Forner
BACKGROUND: Treatment satisfaction in patients with relapsing-remitting multiple sclerosis (RRMS) may impact adherence and thus clinical outcomes. The objective of this study was to measure the satisfaction of patients with RRMS with injectable disease-modifying therapies (DMTs) and to evaluate the factors associated with treatment satisfaction. MATERIAL AND METHODS: In this observational retrospective study conducted in the neurology departments of 35 hospitals throughout Spain, demographic data, disease characteristics, and information on treatment with injectable DMTs were collected at a single scheduled visit...
2017: PloS One
https://read.qxmd.com/read/28427690/factors-associated-with-adherence-to-disease-modifying-therapy-in-multiple-sclerosis-an-observational-survey-from-a-referral-center-in-lithuania
#13
JOURNAL ARTICLE
Neringa Duchovskiene, Dalia Mickeviciene, Giedre Jurkeviciene, Birute Dirziuviene, Renata Balnyte
AIM OF THE STUDY: To investigate adherence to disease modifying therapy (DMT) in Lithuanian population of multiple sclerosis patients and factors associated to it. METHODS: Patients receiving one of the following DMT's: Interferon β 1a (Rebif) 44 micrograms three times a week subdermally (s/c) or Interferon β 1a (Avonex) 30 micrograms weekly intramuscularly (i/m), or Interferon β 1b (Betaferon, Extavia) 250 micrograms once in two days s/c, or Glatiramer acetate (Copaxone) 20mg daily s/c, were presented with a questionnaire inquiring their demographic and clinical characteristics and adherence to treatment profile, as well as HAD scale and SF-36 questionnaire...
April 2017: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/28170401/clinical-practice-of-analysis-of-anti-drug-antibodies-against-interferon-beta-and-natalizumab-in-multiple-sclerosis-patients-in-europe-a-descriptive-study-of-test-results
#14
JOURNAL ARTICLE
Jenny Link, Ryan Ramanujam, Michael Auer, Malin Ryner, Signe Hässler, Delphine Bachelet, Cyprien Mbogning, Clemens Warnke, Dorothea Buck, Poul Erik Hyldgaard Jensen, Claudia Sievers, Kathleen Ingenhoven, Nicolas Fissolo, Raija Lindberg, Verena Grummel, Naoimh Donnellan, Manuel Comabella, Xavier Montalban, Bernd Kieseier, Per Soelberg Sørensen, Hans-Peter Hartung, Tobias Derfuss, Andy Lawton, Dan Sikkema, Marc Pallardy, Bernhard Hemmer, Florian Deisenhammer, Philippe Broët, Pierre Dönnes, Julie Davidson, Anna Fogdell-Hahn
Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of multiple sclerosis (MS) in several European countries. ADA data generated in Europe during the more than 10 years of ADA monitoring in MS patients treated with interferon beta (IFNβ) and natalizumab have been pooled and characterized through collaboration within a European consortium. The aim of this study was to report on the clinical practice of ADA testing in Europe, considering the number of ADA tests performed and type of ADA assays used, and to determine the frequency of ADA testing against the different drug preparations in different countries...
2017: PloS One
https://read.qxmd.com/read/27828855/the-cross-reactivity-of-binding-antibodies-with-different-interferon-beta-formulations-used-as-disease-modifying-drugs-in-multiple-sclerosis-patients
#15
JOURNAL ARTICLE
Agnieszka Wencel-Warot, Slawomir Michalak, Marcin Warot, Alicja Kalinowska-Lyszczarz, Radoslaw Kazmierski
Interferon beta (IFNb) preparations are commonly used as first-line therapy in relapsing-remitting multiple sclerosis (RRMS). They are, however, characterized by limited efficacy, partly due to the formation of anti-IFNb antibodies in patients.In this pilot study, we assessed with the ELISA method the presence of the binding antibodies (BAbs) against interferon beta after 2 years of therapy with subcutaneous interferon beta 1a (Rebif) in 49 RRMS patients. Antibody levels were established again within 1 year after treatment withdrawal...
November 2016: Medicine (Baltimore)
https://read.qxmd.com/read/27695075/risk-factors-for-poor-adherence-to-betaferon%C3%A2-treatment-in-patients-with-relapsing-remitting-multiple-sclerosis-or-clinically-isolated-syndrome
#16
JOURNAL ARTICLE
Łukasz Jernas, Jacek Wencel, Andrzej Wiak, Marek Bieniek, Halina Bartosik-Psujek
INTRODUCTION: Adherence to treatment, including early treatment discontinuation, in patients with multiple sclerosis or clinically isolated syndrome can be affected by: treatment tolerability, route of drug administration, patient age, disease duration, comorbidities, medical care, and support from their caregivers. AIM: This study aimed to identify the risk factors for poor adherence to Betaferon® treatment, including early discontinuation and omitting doses. MATERIALS AND METHODS: 852 adult patients treated with Betaferon participated in this 24-month study...
2016: PloS One
https://read.qxmd.com/read/27511182/the-11-year-long-term-follow-up-study-from-the-randomized-benefit-cis-trial
#17
RANDOMIZED CONTROLLED TRIAL
Ludwig Kappos, Gilles Edan, Mark S Freedman, Xavier Montalbán, Hans-Peter Hartung, Bernhard Hemmer, Edward J Fox, Frederik Barkhof, Sven Schippling, Andrea Schulze, Dirk Pleimes, Christoph Pohl, Rupert Sandbrink, Gustavo Suarez, Eva-Maria Wicklein
OBJECTIVE: To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS) or after a short delay. METHODS: Participants in BENEFIT (Betaferon/Betaseron in Newly Emerging MS for Initial Treatment) were randomly assigned to receive interferon beta-1b (early treatment) or placebo (delayed treatment). After conversion to clinically definite multiple sclerosis (CDMS) or 2 years, patients on placebo could switch to interferon beta-1b or another treatment...
September 6, 2016: Neurology
https://read.qxmd.com/read/27112783/betaferon-in-chronic-viral-cardiomyopathy-bicc-trial-effects-of-interferon-%C3%AE-treatment-in-patients-with-chronic-viral-cardiomyopathy
#18
RANDOMIZED CONTROLLED TRIAL
Heinz-Peter Schultheiss, Cornelia Piper, Olaf Sowade, Finn Waagstein, Joachim-Friedrich Kapp, Karl Wegscheider, Georg Groetzbach, Matthias Pauschinger, Felicitas Escher, Eloisa Arbustini, Harald Siedentop, Uwe Kuehl
BACKGROUND: Chronic viral infections of the heart are considered one antecedent event leading to progressive dysfunction of the myocardium, often with an impaired prognosis due to a virus- or immune-mediated myocardial injury. Symptomatic treatment does not influence the viral cause of heart failure, and the effect of antiviral treatment has not been determined, yet. METHODS AND RESULTS: In this phase II study 143 patients with symptoms of heart failure and biopsy-based confirmation of the enterovirus (EV), adenovirus, and/or parvovirus B19 genomes in their myocardial tissue were randomly assigned to double-blind treatment, and received either placebo (n = 48) or 4 × 10(6) (n = 49) and 8 × 10(6) IU (n = 46) interferon beta-1b (IFN-β-1b) for 24 weeks, in addition to standard heart failure treatment...
September 2016: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://read.qxmd.com/read/26835734/immunogenicity-of-recombinant-human-interferon-beta-1b-in-immune-tolerant-transgenic-mice-corresponds-with-the-biophysical-characteristics-of-aggregates
#19
COMPARATIVE STUDY
Mohadeseh Haji Abdolvahab, Ahmad Fazeli, Andhyk Halim, Ahmad S Sediq, Mohammad Reza Fazeli, Huub Schellekens
Determining to what extent biophysical characteristics of aggregates affect immunogenicity of therapeutic interferon beta-1b. Three recombinant human interferon beta-1b (rhIFNβ-1b) samples with different levels of aggregates generated by copper oxidation, thermal stress, or left untreated, as well as Avonex(®) drug substance and Betaferon(®) drug product, were injected intraperitoneally in nontransgenic and interferon beta transgenic FVB/N mice 5 times per week for 3 weeks. Antibodies against interferon beta were measured using enzyme-linked immunosorbent assay...
April 2016: Journal of Interferon & Cytokine Research
https://read.qxmd.com/read/26824268/an-albumin-free-formulation-for-escherichia-coli-derived-interferon-beta-1b-with-decreased-immunogenicity-in-immune-tolerant-mice
#20
JOURNAL ARTICLE
Mohadeseh Haji Abdolvahab, Ahmad Fazeli, Mazda Radmalekshahi, M Reza Nejadnik, Mohammad Reza Fazeli, Huub Schellekens
Human serum albumin (HSA)-free formulation of Escherichia coli-derived human interferon beta (IFNβ-1b) with a high percentage of monomeric protein and low immunogenicity is developed and characterized in the current study. UV spectroscopy, fluorescence spectroscopy, dynamic light scattering, sodium dodecyl sulfate polyacrylamide gel electrophoresis, Western blotting, Micro-Flow Imaging, resonant mass measurement, size exclusion, and reversed-phase high performance liquid chromatographies were applied to assess the effect of excipients on the stability of IFNβ-1b to establish a HSA-free formulation...
March 2016: Journal of Interferon & Cytokine Research
keyword
keyword
81806
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.